Proposed Data Collections Submitted for Public Comment and Recommendations, 12057-12059 [2012-4566]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 39 / Tuesday, February 28, 2012 / Notices
institutions that are located in the
Caribbean or the United Kingdom.
Estimated annual reporting hours:
574 hours.
Estimated average hours per response:
3.5 hours.
Number of respondents: 41.
General description of report: This
information collection is required (12
U.S.C. 248(a)(2), 461, 602, and 625) and
is given confidential treatment (5 U.S.C.
552(b)(4)).
Abstract: The FR 2502q collects data
quarterly on the geographic distribution
of the assets and liabilities of major U.K.
or Caribbean branches and subsidiaries
of U.S. commercial banks, bank holding
companies, including financial holding
companies, and of banking Edge and
agreement corporations. Data from this
reporting form comprise a piece of the
flow of funds data that are compiled by
the Federal Reserve. FR 2502q data also
helps the Federal Reserve understand
the nature of activities of foreign offices
of U.S. banks, particularly the scope of
cross-border activity that is conducted
by different foreign offices in the United
Kingdom and the Caribbean.
Current Actions: On December 8, 2011
the Federal Reserve published a notice
in the Federal Register (76 FR 76730)
requesting public comment for 60 days
on the extension, with revision, of the
Quarterly Report of Assets and
Liabilities of Large Foreign Offices of
U.S. Banks. The comment period for
this notice expired on February 6, 2012.
The Federal Reserve did not receive any
comments. The revisions will be
implemented as proposed.
Board of Governors of the Federal Reserve
System, February 22, 2012.
Jennifer J. Johnson,
Secretary of the Board.
[FR Doc. 2012–4527 Filed 2–27–12; 8:45 am]
BILLING CODE 6210–01–P
FEDERAL RESERVE SYSTEM
tkelley on DSK3SPTVN1PROD with NOTICES
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
The notificants listed below have
applied under the Change in Bank
Control Act (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
notices are set forth in paragraph 7 of
the Act (12 U.S.C. 1817(j)(7)).
The notices are available for
immediate inspection at the Federal
Reserve Bank indicated. The notices
also will be available for inspection at
the offices of the Board of Governors.
VerDate Mar<15>2010
20:10 Feb 27, 2012
Jkt 226001
Interested persons may express their
views in writing to the Reserve Bank
indicated for that notice or to the offices
of the Board of Governors. Comments
must be received not later than March
14, 2012.
A. Federal Reserve Bank of Chicago
(Colette A. Fried, Assistant Vice
President) 230 South LaSalle Street,
Chicago, Illinois 60690–1414:
1. Perry Hodgson, Alexander
Hodgson, and Raymond Hodgson, all of
Charlevoix, Michigan; to join the
existing Hodgson control group and to
retain and acquire voting shares of
Charlevoix First Corporation, and
indirectly retain and acquire voting
shares of Charlevoix State Bank,
Charlevoix, Michigan.
Board of Governors of the Federal Reserve
System, February 23, 2012.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 2012–4616 Filed 2–27–12; 8:45 am]
BILLING CODE 6210–01–P
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The applications will also be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
12057
Governors not later than March 23,
2012.
A. Federal Reserve Bank of Richmond
(Adam M. Drimer, Assistant Vice
President) 701 East Byrd Street,
Richmond, Virginia 23261–4528:
1. SCBT Financial Corporation,
Columbia, South Carolina; to acquire
100 percent of the voting shares of
Peoples Bancorporation, Inc., and
thereby indirectly acquire voting shares
of The Peoples National Bank, both in
Easley, South Carolina, Bank of
Anderson, NA, Anderson, South
Carolina, and Seneca National Bank,
Seneca, South Carolina.
B. Federal Reserve Bank of Atlanta
(Chapelle Davis, Assistant Vice
President) 1000 Peachtree Street NE.,
Atlanta, Georgia 30309:
1. United Group of Central Florida II,
LLC, Longwood, Florida, to become a
bank holding company by acquiring 100
percent of the voting shares of Citizens
Bancorp of Oviedo, Inc., and thereby
indirectly acquire voting shares of
Citizens Bank of Florida, both in
Oviedo, Florida.
Board of Governors of the Federal Reserve
System, February 23, 2012.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 2012–4617 Filed 2–27–12; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–12–12EL]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–7570 and
send comments to Kimberly S. Lane,
CDC Reports Clearance Officer, 1600
Clifton Road, MS–D74, Atlanta, GA
30333 or send an email to omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
E:\FR\FM\28FEN1.SGM
28FEN1
12058
Federal Register / Vol. 77, No. 39 / Tuesday, February 28, 2012 / Notices
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
Critical Thinking and Cultural
Affirmation (CTCA): Evaluation of a
Locally Developed HIV Prevention
Intervention—New—National Center for
HIV/AIDS, Viral Hepatitis, STD, TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
In 2005, the Centers for Disease
Control and Prevention (CDC) reported
that 80,187 African Americans were
diagnosed with HIV/AIDS, which
represents 51% of persons diagnosed.
African-American men with HIV/AIDS
represented 44% of all cases among
males (Centers for Disease Control and
Prevention [CDC], 2005). These statistics
have been consistently disproportional
since the late 1990s, with African
Americans bearing the greatest burden
of new HIV cases in most regions of the
United States. The Centers for Disease
Control and Prevention estimates that at
the end of 2006, Blacks were
disproportionately affected by HIV. The
2006 HIV infection rate in Blacks was
nearly twice the rate of Whites (92 out
of every 100,000 Blacks compared to 48
per 100,000 Whites and 31 per 100,000
Hispanics). Among males, Black males
accounted for the largest number of
diagnosed HIV infections and have the
highest HIV infection rate of any race/
ethnicity group (144 per 100,000,
compared to 94 per 100,000 for White
males and 50 per 100,000 for Hispanic
males.
While many HIV prevention and
intervention studies include samples of
African-American men and AfricanAmerican Men who have Sex with Men
(AAMSM), beyond demonstrating
disparities in seroprevalence between
and among racial groups, few have been
specifically designed and evaluated for
efficacy among African-American men.
Because few HIV prevention
interventions targeting AAMSM have
been developed and rigorously
evaluated, while their HIV infection
rates remain disproportionately high
and continue to rise, identifying
effective interventions for AAMSM is a
public health imperative.
The purpose of this project is to test
the efficacy of an HIV transmission
prevention intervention for reducing
sexual risk among African American
men who have sex with men in Chicago,
Illinois. The intervention is a 3-day
weekend retreat, group-level CTCA
intervention that combines cultural
affirmation with critical thinking and
empowerment, to increase reasoning
skill, problem solving capacity, selfprotective behavior change, and wellbeing which facilitates the reduction of
risky sexual behaviors. A convenience
sample of 438 AAMSM will be recruited
to participate in the study. We
anticipate recruiting potential
participants for the CTCA RCT through
a variety of community venues, using
both active (i.e., venue outreach) and
passive (i.e., referral, flyers/handcards,
Internet) recruitment techniques. The
intervention will be evaluated using
baseline, 3-month and 6-month follow
up assessments. This project will also
conduct exit surveys to identify men
who were more favorable—men who
agreed with positive comments about
the intervention and those who were
less favorable—men who disagreed with
positive comments about the
intervention. Exit interviews will be
conducted with 15 favorable and 15 less
favorable men identified by the Exit
Survey to help understand participants’
experiences with the CTCA intervention
Number of
respondents
tkelley on DSK3SPTVN1PROD with NOTICES
Type of respondent
Form name
Prospective Study Participant ...........
Prospective Study Participant ...........
Prospective Study Participant ...........
Enrolled Study Participant ................
Enrolled Study Participant ................
Enrolled Study Participant ................
Enrolled Study Participant ................
Enrolled Study Participant ................
Enrolled Study Participant ................
Enrolled Study Participant ................
Pre-Screening Form .........................
Full-Screening Form .........................
Brief Locator Form ...........................
Record Locator Form .......................
Baseline Assessment .......................
3-month Follow-up Assessment .......
6-month Follow-up Assessment .......
Participant Evaluation Forms ...........
Exit Survey .......................................
Exit Interview ....................................
VerDate Mar<15>2010
20:10 Feb 27, 2012
Jkt 226001
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
and their thoughts about the content of
the intervention and ways in which it
could be improved. Using the
participant responses to the exit survey,
we will categorize participants into two
categories: favorable (those men
reporting a favorable reaction to the
intervention) and unfavorable (those
men reporting an unfavorable reaction
to the intervention). Once we have 50
participants in each category, we will
randomly select 15 participants from
each group and invite them to
participate in the exit interview. We
anticipate that we will need to repeat
these procedures and extend an
invitation to at least 65 participants in
order to reach and successfully
interview 15 participants in each group.
CDC is requesting approval for a 3year clearance for data collection. Data
collection will begin November 2012
and end January 2015. The data
collection system involves a pre and full
screening, brief locator information,
record locator information, baseline
assessment, 3-month follow-up
assessment, 6-month follow-up
assessment, participant evaluation
forms, exit survey, and exit interviews.
An estimated 700 men will be prescreened and 500 will be full-screened
for eligibility in order to enroll 438 men.
The baseline and follow-up
questionnaires will be administered
electronically using audio computer
assisted self-interview (ACASI). The
ACASI interview includes questions
about participants’ socio-demographic
information, health and healthcare,
sexual activity, substance use, and other
psychosocial issues. The duration of
each baseline, 3-month, and 6-month
assessment is estimated to be 60
minutes; the exit survey 10 minutes; the
exit interview 30 minutes; pre-screening
form 5 minutes; full-screening form 10
minutes; brief locator information form
5 minutes; record locator information
form 10 minutes; each participant
evaluation survey 5 minutes.
There is no cost to participants other
than their time.
Number
responses per
respondent
700
515
515
438
438
395
350
438
350
30
E:\FR\FM\28FEN1.SGM
1
1
1
1
1
1
1
6
1
1
28FEN1
Average
burden per
respondent
(in hours)
5/60
10/60
5/60
10/60
1
1
1
5/60
10/60
30/60
Total annual
burden in
hours
58
86
43
73
438
395
350
219
58
15
Federal Register / Vol. 77, No. 39 / Tuesday, February 28, 2012 / Notices
Form name
Number of
respondents
Number
responses per
respondent
Average
burden per
respondent
(in hours)
...........................................................
........................
........................
........................
Type of respondent
Total ...........................................
Kimberly S. Lane,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2012–4566 Filed 2–27–12; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0171]
Using Innovative Technologies and
Other Conditions of Safe Use To
Expand Which Drug Products Can Be
Considered Nonprescription; Public
Hearing
AGENCY:
Food and Drug Administration,
HHS.
Notice of public hearing; request
for comments.
ACTION:
The U.S. Food and Drug
Administration (FDA or the Agency) is
announcing a public hearing to obtain
input on a new paradigm we are
considering. Under this paradigm, the
Agency would approve certain drugs
that would otherwise require a
prescription for nonprescription use
(also known as over-the-counter or OTC)
under conditions of safe use. These
conditions of safe use would be specific
to the drug product and might require
sale in certain pre-defined health care
settings, such as a pharmacy. This
public hearing is being held to obtain
information and comments from the
public on the feasibility of this
paradigm and its potential benefits and
costs.
DATES: Public Hearing: The public
hearing will be held on March 22 and
23, 2012, from 9 a.m. to 4 p.m. The
meeting may be extended or may end
early depending on the level of public
participation.
Presentations and Comments: Submit
either electronic or written requests for
oral presentations and comments by
March 9, 2012. (See section IV of this
document for details.) Either electronic
or written comments will be accepted
after the hearing until May 7, 2012 (See
section VI of this document for details.)
ADDRESSES: The public hearing will be
held at FDA’s White Oak Campus,
10903 New Hampshire Ave., Bldg. 31,
tkelley on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
20:10 Feb 27, 2012
Jkt 226001
Rm. 1503, Silver Spring, MD, 20993–
0002.
Comments and Transcripts: Submit
either electronic or written comments to
the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://www.
regulations.gov. All comments should
be identified with the docket number
found in brackets in the heading of this
document. Transcripts of the hearing
will be available for review at the
Division of Dockets Management and on
the Internet at https://www.
regulations.gov approximately 45 days
after the hearing.
FOR FURTHER INFORMATION CONTACT: Lee
Lemley, Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20903–0002,
301–796–3441, Fax: 301–847–8753,
email: OTCTechnologiesPublic
Meeting@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: FDA is
announcing a public hearing to obtain
input on a potential new paradigm
under which the Agency would approve
certain drugs that would otherwise
require a prescription for
nonprescription use under conditions of
safe use specific to the drug product.
Some drugs approved in this manner
might require sale in certain pre-defined
health care settings, such as a pharmacy.
I. Background
A. Prescription and Nonprescription
Drugs
Under the Federal Food, Drug, and
Cosmetic Act (FD&C Act), FDA
approves new drugs under section 505
(21 U.S.C. 355) either as prescription or
nonprescription. Under section
503(b)(1)(A) of the FD&C Act (21 U.S.C.
353(b)(1)(A)), a drug must be dispensed
by prescription if, ‘‘because of its
toxicity or other potentiality for harmful
effect, or the method of its use, or the
collateral measures necessary to its use,
[it] is not safe for use except under the
supervision of a practitioner licensed by
law to administer such drug.’’ Under
sections 505(d)(1) and (d)(4), FDA has
considerable latitude in determining
whether the information submitted as
part of a new drug application (NDA) is
sufficient to ensure that a drug is safe
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
12059
Total annual
burden in
hours
1735
for use under its proposed labeling. FDA
also makes a determination under
503(b) as to whether the product meets
the criteria for prescription-only
dispensing.
Prescription drugs are dispensed
upon receipt of a prescription from a
practitioner licensed by law to
administer the drug (which may include
health care professionals such as
physicians, nurse practitioners,
physician’s assistants, and others whom
we will refer to here as practitioners or
prescribers). (See 21 U.S.C. 353(b).) In
many instances, under the current
regulatory system, a patient has to
obtain at least the initial prescription,
and in some cases, prescription refills,
from a practitioner through an in person
interaction. Obtaining a refill for other
prescription drugs involves at least a
telephone call or other communication
with the practitioner. In contrast,
nonprescription drugs (sometimes
referred to as over-the-counter or OTC
products) can be purchased by
consumers in pharmacies,
supermarkets, and other retail
establishments without the need for a
prescription. Currently, consumers can
purchase nonprescription drugs from a
retailer for diseases or conditions that
do not meet the statutory criteria for
prescription products and that are safe
and effective for use in self-medication
as directed in the labeling. (See 21
U.S.C. 353(b).) Generally, OTC products:
(1) Are available to treat diseases or
conditions that can be self-diagnosed
without a prior interaction with a
practitioner, (2) are not associated with
toxicities that require an evaluation of
the benefits and risks by a practitioner;
and (3) do not require a practitioner’s
input for use.
B. Undertreatment of Diseases and
Other Effects on the Health Care System
Undertreatment of many common
diseases or conditions in the United
States is a well recognized public health
problem. Increasing the number of
people who are able to obtain for the
first time and those who continue on
necessary drug therapy could provide
improved health outcomes. The
requirement to obtain a prescription for
appropriate medication (and to make
one or more visits to a practitioner) may
contribute to undertreatment of certain
common medical conditions including
E:\FR\FM\28FEN1.SGM
28FEN1
]]>Agencies
[Federal Register Volume 77, Number 39 (Tuesday, February 28, 2012)]
[Notices]
[Pages 12057-12059]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-4566]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-12-12EL]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-7570
and send comments to Kimberly S. Lane, CDC Reports Clearance Officer,
1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send an email to
omb@cdc.gov.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have
[[Page 12058]]
practical utility; (b) the accuracy of the agency's estimate of the
burden of the proposed collection of information; (c) ways to enhance
the quality, utility, and clarity of the information to be collected;
and (d) ways to minimize the burden of the collection of information on
respondents, including through the use of automated collection
techniques or other forms of information technology. Written comments
should be received within 60 days of this notice.
Proposed Project
Critical Thinking and Cultural Affirmation (CTCA): Evaluation of a
Locally Developed HIV Prevention Intervention--New--National Center for
HIV/AIDS, Viral Hepatitis, STD, TB Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
In 2005, the Centers for Disease Control and Prevention (CDC)
reported that 80,187 African Americans were diagnosed with HIV/AIDS,
which represents 51% of persons diagnosed. African-American men with
HIV/AIDS represented 44% of all cases among males (Centers for Disease
Control and Prevention [CDC], 2005). These statistics have been
consistently disproportional since the late 1990s, with African
Americans bearing the greatest burden of new HIV cases in most regions
of the United States. The Centers for Disease Control and Prevention
estimates that at the end of 2006, Blacks were disproportionately
affected by HIV. The 2006 HIV infection rate in Blacks was nearly twice
the rate of Whites (92 out of every 100,000 Blacks compared to 48 per
100,000 Whites and 31 per 100,000 Hispanics). Among males, Black males
accounted for the largest number of diagnosed HIV infections and have
the highest HIV infection rate of any race/ethnicity group (144 per
100,000, compared to 94 per 100,000 for White males and 50 per 100,000
for Hispanic males.
While many HIV prevention and intervention studies include samples
of African-American men and African-American Men who have Sex with Men
(AAMSM), beyond demonstrating disparities in seroprevalence between and
among racial groups, few have been specifically designed and evaluated
for efficacy among African-American men. Because few HIV prevention
interventions targeting AAMSM have been developed and rigorously
evaluated, while their HIV infection rates remain disproportionately
high and continue to rise, identifying effective interventions for
AAMSM is a public health imperative.
The purpose of this project is to test the efficacy of an HIV
transmission prevention intervention for reducing sexual risk among
African American men who have sex with men in Chicago, Illinois. The
intervention is a 3-day weekend retreat, group-level CTCA intervention
that combines cultural affirmation with critical thinking and
empowerment, to increase reasoning skill, problem solving capacity,
self-protective behavior change, and well-being which facilitates the
reduction of risky sexual behaviors. A convenience sample of 438 AAMSM
will be recruited to participate in the study. We anticipate recruiting
potential participants for the CTCA RCT through a variety of community
venues, using both active (i.e., venue outreach) and passive (i.e.,
referral, flyers/handcards, Internet) recruitment techniques. The
intervention will be evaluated using baseline, 3-month and 6-month
follow up assessments. This project will also conduct exit surveys to
identify men who were more favorable--men who agreed with positive
comments about the intervention and those who were less favorable--men
who disagreed with positive comments about the intervention. Exit
interviews will be conducted with 15 favorable and 15 less favorable
men identified by the Exit Survey to help understand participants'
experiences with the CTCA intervention and their thoughts about the
content of the intervention and ways in which it could be improved.
Using the participant responses to the exit survey, we will categorize
participants into two categories: favorable (those men reporting a
favorable reaction to the intervention) and unfavorable (those men
reporting an unfavorable reaction to the intervention). Once we have 50
participants in each category, we will randomly select 15 participants
from each group and invite them to participate in the exit interview.
We anticipate that we will need to repeat these procedures and extend
an invitation to at least 65 participants in order to reach and
successfully interview 15 participants in each group.
CDC is requesting approval for a 3-year clearance for data
collection. Data collection will begin November 2012 and end January
2015. The data collection system involves a pre and full screening,
brief locator information, record locator information, baseline
assessment, 3-month follow-up assessment, 6-month follow-up assessment,
participant evaluation forms, exit survey, and exit interviews. An
estimated 700 men will be pre-screened and 500 will be full-screened
for eligibility in order to enroll 438 men. The baseline and follow-up
questionnaires will be administered electronically using audio computer
assisted self-interview (ACASI). The ACASI interview includes questions
about participants' socio-demographic information, health and
healthcare, sexual activity, substance use, and other psychosocial
issues. The duration of each baseline, 3-month, and 6-month assessment
is estimated to be 60 minutes; the exit survey 10 minutes; the exit
interview 30 minutes; pre-screening form 5 minutes; full-screening form
10 minutes; brief locator information form 5 minutes; record locator
information form 10 minutes; each participant evaluation survey 5
minutes.
There is no cost to participants other than their time.
----------------------------------------------------------------------------------------------------------------
Number Average burden Total annual
Type of respondent Form name Number of responses per per respondent burden in
respondents respondent (in hours) hours
----------------------------------------------------------------------------------------------------------------
Prospective Study Participant. Pre-Screening 700 1 5/60 58
Form.
Prospective Study Participant. Full-Screening 515 1 10/60 86
Form.
Prospective Study Participant. Brief Locator 515 1 5/60 43
Form.
Enrolled Study Participant.... Record Locator 438 1 10/60 73
Form.
Enrolled Study Participant.... Baseline 438 1 1 438
Assessment.
Enrolled Study Participant.... 3-month Follow- 395 1 1 395
up Assessment.
Enrolled Study Participant.... 6-month Follow- 350 1 1 350
up Assessment.
Enrolled Study Participant.... Participant 438 6 5/60 219
Evaluation
Forms.
Enrolled Study Participant.... Exit Survey..... 350 1 10/60 58
Enrolled Study Participant.... Exit Interview.. 30 1 30/60 15
-------------------------------
[[Page 12059]]
Total..................... ................ .............. .............. .............. 1735
----------------------------------------------------------------------------------------------------------------
Kimberly S. Lane,
Reports Clearance Officer, Centers for Disease Control and Prevention.
[FR Doc. 2012-4566 Filed 2-27-12; 8:45 am]
BILLING CODE 4163-18-P
